Interestingly, while FXYD2 is downregulated in ccRCC, it is upregulated in other tumor types, such as colorectal, hepatocellular, and ovarian clear cell carcinomas, where its high expression correlates with advanced disease and poor prognosis [61]. This evidence concerns the gene FXYD2 and nonpapillary renal cell carcinoma.